All In Biotech

Drug Trial Radar · NCT07863167

An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

660

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2030

Sponsor

Sponsor type
Industry
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • adebrelimab + SHR-A2009Drug

    adebrelimab + SHR-A2009

  • paclitaxel or pemetrexed combined with carboplatin +adebrelimabDrug

    paclitaxel or pemetrexed combined with carboplatin +adebrelimab

  • adebrelimab + SHR-A2009Drug

    adebrelimab + SHR-A2009 (longer-interval regimen arm)

  • adebrelimab + SHR-A2009Drug

    adebrelimab + SHR-A2009 (shorter-interval regimen arm)

  • adebrelimabDrug

    adebrelimab

  • adebeliizumab + SHR-A2009Drug

    adebeliizumab + SHR-A2009 (longer-interval regimen arm)

  • adebeliizumab + SHR-A2009Drug

    adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

  • adebeliizumab + platinum-containing double chemotherapyDrug

    adebeliizumab + platinum-containing double chemotherapy

  • almonertinib combined with SHR-A2009Drug

    almonertinib combined with SHR-A2009 (longer-interval regimen arm)

  • almonertinib combined with SHR-A2009Drug

    almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

  • almonertinibDrug

    almonertinib

  • SHR-A2009 combined with almonertinibDrug

    SHR-A2009 combined with almonertinib

  • almonertinib monotherapyDrug

    almonertinib monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A1 : pCR rate;Time frame: about 24 months
  2. Part A2 : 2-year DFS rate;Time frame: about 24 months
  3. Part A3 : pCR rate and 18-month EFS rate;Time frame: about 18 months
  4. Part B1 : 2-year DFS rate.Time frame: about 24 months
  5. Part B2 : MPR rate.Time frame: about 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.